The stock of Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) last traded at $1.35, up 4.65% from the previous session.
LXRX stock price is now 73.05% away from the 50-day moving average and 57.51% away from the 200-day moving average. The market capitalization of the company currently stands at $490.29M.
With the price target reduced from $2 to $1, Leerink Partners Downgraded its rating from Outperform to Market Perform for Lexicon Pharmaceuticals Inc (NASDAQ: LXRX). On June 17, 2024, H.C. Wainwright recently initiated its ‘Buy’ rating on the stock quoting a target price of $10, while ‘Leerink Partners’ rates the stock as ‘Outperform’
In other news, COATS LONNEL, Former Affiliate bought 300,000 shares of the company’s stock on Aug 15 ’24. The stock was bought for $480,000 at an average price of $1.60. A total of 51.26% of the company’s stock is owned by insiders.
During the past 12 months, Lexicon Pharmaceuticals Inc has had a low of $0.28 and a high of $2.45. As of last week, the company has a debt-to-equity ratio of 0.86, a current ratio of 2.22, and a quick ratio of 2.22. The fifty day moving average price for LXRX is $0.7472 and a two-hundred day moving average price translates $0.86345 for the stock.
The latest earnings results from Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) was released for 2025-03-31. The net profit margin was -568.04% and return on equity was -86.09% for LXRX. For the current quarter, analysts expect LXRX to generate $4.87M in revenue.
